SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 8, 2016
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation or organization)
333 LAKESIDE DRIVE,
FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
||Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425) |
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 5CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Appointment of Certain Officers; Election of Directors; Compensatory Arrangements of Certain Officers
||Appointment of Certain Officers |
||Compensation Arrangements of Certain Officers |
On March 8, 2016, the Compensation
Committee (the Committee) of the Board of Directors of Gilead Sciences, Inc. approved amendments to the Gilead Sciences, Inc. Severance Plan (the Severance Plan) to address the Severance Plans operation in light of the
previously announced appointment of John C. Martin, Ph.D., to serve as Executive Chairman, and of John F. Milligan, Ph.D., to serve as President and Chief Executive Officer effective March 10, 2016. As amended, the Severance Plan provides to
Drs. Martin and Milligan the same level of benefits that were previously provided to Dr. Martin based on his service as Chief Executive Officer (generally, two or three times base salary plus annual bonus). In addition, the amendment eliminates
the golden parachute excise tax gross-up otherwise available to certain participants, including Drs. Martin and Milligan, subject to the terms of the Severance Plan, and makes other technical or clarifying revisions.
The foregoing description is qualified in its entirety by reference to the Severance Plan filed as Exhibit 10.1 to this Report.
Section 9FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
||Gilead Sciences, Inc. Severance Plan amended and restated on March 8, 2016|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|GILEAD SCIENCES, INC.|
|/s/ Robin L. Washington|
Robin L. Washington
Executive Vice President and
Date: March 11, 2016